605507 Guobang Pharma Ltd.
- 17.93
- -0.04-0.22%
Guobang Pharma Ltd. News
Guobang Pharmaceutical (605507.SH): A total cost of 995.15,900 yuan to buy back 1.1% of the shares
Gelonghui, May 31, 丨 Guobang Pharmaceutical (605507.SH) announced that as of May 31, 2024, the company had repurchased a total of 6,127,000 shares through centralized bidding transactions. The repurchased shares accounted for 1.10% of the company's total share capital. The highest transaction price was 18.66 yuan/share, the lowest price was 13.05 yuan/share, and the total amount paid was 99,515,878.00 yuan (not including transaction fees).
Guobang Pharmaceutical (605507.SH): A total cost of 94.99 million yuan to buy back 1.05% of the shares
Gelonghui, May 23丨Guobang Pharmaceutical (605507.SH) announced that as of May 22, 2024, the company had repurchased 5,875,200 shares through centralized bidding transactions. The repurchased shares accounted for 1.05% of the company's total share capital. The highest price of the repurchase transaction was 18.66 yuan/share, the lowest price was 13.05 yuan/share, and the total amount of capital paid was 94,990,928 yuan (not including transaction fees).
Private Companies Among Guobang Pharma Ltd.'s (SHSE:605507) Largest Shareholders, Saw Gain in Holdings Value After Stock Jumped 4.6% Last Week
Key Insights Guobang Pharma's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public 55% of the business is held by the top 4 s
Analysts Just Slashed Their Guobang Pharma Ltd. (SHSE:605507) EPS Numbers
The analysts covering Guobang Pharma Ltd. (SHSE:605507) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. Revenue and
Guobang Pharmaceutical (605507.SH): Zhejiang Minjin Henghua and Silk Road Fund reduced their holdings by a total of 1.82%
Gelonghui, May 8, 丨 Guobang Pharmaceutical (605507.SH) announced that it has received a “Notice Letter on the Progress of the Shareholding Reduction Plan and Changes in Equity by More than 1%” from Zhejiang Minjin Investment Henghua and Silk Road Fund. The current holdings reduction plan reduced the company's holdings by a total of 10,171,800 shares, with a change ratio of 1.82% of the company's total share capital. The amount of holdings reduction this time is over half. The current holdings reduction plan has not yet been implemented. After this change in equity, Zhejiang Mintou Henghua and Silk Road Fund held 20,887,083 shares of the company, accounting for 3.74% of the company's total share capital.
Guobang Pharmaceutical (605507.SH): A total of 3.468 million shares have been repurchased as of April 30
Gelonghui, April 30, 丨 Guobang Pharmaceutical (605507.SH) announced that as of April 30, 2024, the company had repurchased a total of 3.468 million shares through centralized bidding transactions. The repurchased shares accounted for 0.62% of the company's total share capital. The highest transaction price was 15.69 yuan/share, the lowest price was 13.05 yuan/share, and the total amount paid was 51.4603 million yuan (excluding transaction fees).
We Think Guobang Pharma (SHSE:605507) Is Taking Some Risk With Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' When we thi
Gelonghui Announcements Selected | Everweft Lithium Energy: Net profit in 2023 will increase 15.42% to 4,050 billion yuan, and plans to pay 10 to 5 yuan; Guobang Pharmaceutical: Zhejiang Minjin Henghua and Silk Road Fund plan to reduce their holdings by n
[Investment Project] Wanxiang Qianchao (000559.SZ): Wanxiang Qianchao (000559.SZ) announced that it plans to build an R&D and manufacturing project with an annual output of 9 million constant velocity drive shafts. It is proposed to sign a framework agreement with the Wuhu Economic and Technological Development Zone Management Committee on an R&D and manufacturing project with an annual output of 9 million constant velocity drive shafts. The total investment in this project does not exceed 1.5 billion yuan. Hesheng Co., Ltd. (002824.SZ): Guangdong Hesheng New Energy plans to invest 1.5 billion yuan to build Yibin Hesheng NEV high-end components project Hesheng Co., Ltd. (002824.SZ) announced that the company will hold its fourth term of directors on April 18, 2024
Guobang Pharmaceutical (605507.SH): Zhejiang Minjin Investment Henghua and Silk Road Fund plan to reduce their holdings by no more than 3%
Gelonghui, April 18 | Guobang Pharmaceutical (605507.SH) announced that due to their own capital requirements, shareholders Zhejiang Minjin Henghua and Silk Road Fund plan to reduce their holdings of the company's total shares by no more than 16,764,705 shares through centralized bidding and bulk transactions, with a reduction ratio of no more than 3% of the company's total share capital.
Guobang Pharmaceutical (605507.SH): Net profit in 2023 fell 33.49% year on year, and plans to pay 10 to 3 yuan
On April 15, Ge Longhui Pharmaceutical (605507.SH) released its 2023 annual report. During the reporting period, it achieved operating income of 5.349 billion yuan, a year-on-year decrease of 6.49%; net profit attributable to shareholders of listed companies was 612 million yuan, a year-on-year decrease of 33.49%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 592 million yuan, a year-on-year decrease of 34.69%; and basic earnings per share were 1.10 yuan. It is proposed to distribute a cash dividend of RMB 3.00 (tax included) for every 10 shares to all shareholders.
Guobang Pharmaceutical (605507.SH): A total cost of 275.859 million yuan to buy back 0.34% of the shares
Gelonghui, April 2, 丨 Guobang Pharmaceutical (605507.SH) announced that as of March 29, 2024, the company had repurchased 1,923,700 shares through centralized bidding transactions. The repurchased shares accounted for 0.34% of the company's total share capital. The highest transaction price was 15.75 yuan/share, the lowest price was 13.05 yuan/share, and the total amount paid was 27,585,916 yuan (excluding transaction fees).
Guobang Pharma Ltd.'s (SHSE:605507) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
With its stock down 11% over the past three months, it is easy to disregard Guobang Pharma (SHSE:605507). But if you pay close attention, you might find that its key financial indicators look quite
Shareholders of Guobang Pharmaceutical (605507.SH) Zhejiang Mintou Henghua and Silk Road Fund reduced their total shares by 1.02%
Guobang Pharmaceutical (605507.SH) announced that the company's shareholders Zhejiang Mintou Henghua and Silk Road Fund announced on July 4, 2023...
Guobang Pharmaceutical (605507.SH): A total cost of 25.31 million yuan to buy back 0.32% of the shares
Gelonghui, Feb. 29丨Guobang Pharmaceutical (605507.SH) announced that as of February 29, 2024, the company had repurchased 1,773,800 shares through centralized bidding transactions. The repurchased shares accounted for 0.32% of the company's total share capital. The highest transaction price was 15.75 yuan/share, the lowest price was 13.05 yuan/share, and the total amount paid was 25,314,012 yuan.
Guobang Pharmaceutical (605507.SH): Currently, azithromycin production capacity is sufficient
Gelonghui, Feb. 26 | Guobang Pharmaceutical (605507.SH) said on an interactive platform that azithromycin, as one of the company's main pharmaceutical raw materials, is sold to major domestic and international pharmaceutical manufacturers, and has a strong market influence and position. The company currently has sufficient azithromycin production capacity, which can guarantee adequate supply in the market and meet customer needs.
Guobang Pharmaceutical (605507.SH): Wholly-owned subsidiary passed GMP compliance inspection
Gelonghui, Feb. 22丨Guobang Pharmaceutical (605507.SH) announced that Zhejiang Guobang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the drug GMP compliance inspection results notice from the Zhejiang Drug Administration website (Zhejiang 2024 No. 0024). The company now obtained the GMP compliance inspection results, indicating that the production quality management of the company's apixaban API products meets GMP requirements, which will help the company to continue to maintain stable product quality and continuous stable production capacity to meet the market demand for related drugs.
Guobang Pharmaceutical (605507.SH): Initial repurchase of 0.1927% of shares
Gelonghui, February 2, 丨 Guobang Pharmaceutical (605507.SH) announced that on February 2, 2024, the company repurchased 1,076,700 shares for the first time through centralized bidding. The repurchased shares accounted for 0.1927% of the company's total share capital. The highest transaction price was 14.65 yuan/share, the lowest price was 14.31 yuan/share, and the total amount paid was 15,505,013.00 yuan.
Guobang Pharmaceutical (605507.SH) plans to spend 100 million yuan to 200 million yuan to repurchase shares
Guobang Pharmaceutical (605507.SH) issued an announcement. The company plans to spend 100 million yuan to 200 million yuan to repurchase shares. The repurchase price...
Estimating The Fair Value Of Guobang Pharma Ltd. (SHSE:605507)
Key Insights The projected fair value for Guobang Pharma is CN¥14.11 based on Dividend Discount Model Current share price of CN¥15.37 suggests Guobang Pharma is potentially trading close to its fair
Guobang Pharmaceutical (605507.SH): Chairman Qiu Jiajun proposed to buy back 100 million yuan to 200 million yuan of company shares
Gelonghui, January 23, 丨 Guobang Pharmaceutical (605507.SH) announced that on January 23, 2024, the company received a “Letter from Mr. Qiu Jiajun, Chairman of the Company on Proposing Guobang Pharmaceutical Group Co., Ltd. to repurchase the company's shares”. The total capital for repurchasing shares shall not be less than RMB 100 million (inclusive) and not more than RMB 200 million (inclusive). The repurchase price of shares does not exceed 150% of the average trading price of the company's shares in the 30 trading days before the board of directors passed the buyback resolution.
Analysis
Price Target
No Data
